SAGE THERAPEUTICS INC's ticker is SAGE and the CUSIP is 78667J108. A total of 263 filers reported holding SAGE THERAPEUTICS INC in Q1 2021. The put-call ratio across all filers is 2.21 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,684,885 | -60.2% | 81,870 | -9.0% | 0.03% | -65.3% |
| Q2 2023 | $4,231,800 | +68.1% | 90,000 | +50.0% | 0.08% | +56.2% |
| Q1 2023 | $2,517,600 | +190.0% | 60,000 | +123.4% | 0.05% | +300.0% |
| Q2 2022 | $868,000 | -85.9% | 26,862 | -85.6% | 0.01% | -84.0% |
| Q1 2022 | $6,161,000 | -58.7% | 186,097 | -46.9% | 0.08% | -55.1% |
| Q4 2021 | $14,915,000 | +381.0% | 350,621 | +400.9% | 0.17% | +377.1% |
| Q3 2021 | $3,101,000 | -88.9% | 70,000 | -85.7% | 0.04% | -90.4% |
| Q2 2021 | $27,826,000 | +550.9% | 489,800 | +757.3% | 0.36% | +298.9% |
| Q1 2021 | $4,275,000 | +644.8% | 57,130 | +185.6% | 0.09% | +184.4% |
| Q1 2020 | $574,000 | -97.0% | 20,000 | -92.5% | 0.03% | -95.0% |
| Q4 2019 | $19,151,000 | +26.4% | 265,300 | +145.6% | 0.64% | -18.4% |
| Q3 2019 | $15,151,000 | +22.4% | 108,000 | +59.8% | 0.79% | +26.5% |
| Q2 2019 | $12,377,000 | +7.2% | 67,600 | -6.9% | 0.62% | -2.2% |
| Q1 2019 | $11,546,000 | +34.2% | 72,600 | -19.2% | 0.64% | -7.3% |
| Q4 2018 | $8,606,000 | – | 89,850 | – | 0.69% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Finepoint Capital LP | 475,600 | $15,362,000 | 5.31% |
| Integral Health Asset Management, LLC | 412,257 | $13,316,000 | 2.74% |
| Palo Alto Investors LP | 851,409 | $27,501,000 | 2.40% |
| Boxer Capital, LLC | 1,094,000 | $35,336,000 | 2.24% |
| DAFNA Capital Management LLC | 180,306 | $5,824,000 | 1.59% |
| Ikarian Capital, LLC | 250,000 | $8,075,000 | 1.47% |
| Bellevue Group AG | 2,973,178 | $96,034,000 | 1.36% |
| SECTOR GAMMA AS | 118,476 | $3,827,000 | 0.86% |
| Artal Group S.A. | 450,000 | $14,535,000 | 0.78% |
| Diametric Capital, LP | 19,393 | $626,000 | 0.46% |